Interestingly, we found that SSA administration can significantly improve insulin resistance with a compromise in insulin secretion, in patients with both biochemically controlled (posttreatment GH levels < 2.5 μg/l) and uncontrolled (posttreatment GH levels ≥ 2.5 μg/l) acromegaly, which was similar with Giordano et al. [36]. The gene discussed is GH1; the disease is acromegaly.